Dr. Rainer Pooth | Medicine and Dentistry Award | Best Innovation Award

Dr. Rainer Pooth, ICAAN GmbH, Germany

Based on the information provided, Dr. Rainer Pooth appears to be a highly suitable candidate for the “Research for Best Innovation Award” in the pharmaceutical and medical industry. Here’s an assessment of his qualifications:

Publication profile

Professional Experience & Leadership

Dr. Pooth has over 20 years of experience in the global pharmaceutical and medical industry, with a strong track record of leadership in multidisciplinary teams at both global and affiliate levels. His roles as Managing Director, Global Head of Medical/Scientific Affairs, and Head of Global Clinical Development demonstrate his ability to lead and innovate in complex, highly regulated environments. His strategic input in global R&D programs, project management, and regulatory affairs underscores his expertise in driving innovation and ensuring successful product development.

Achievements & Expertise

Dr. Pooth’s achievements include multiple approvals of medicinal products and medical devices across key global markets such as the EU, US, Australia, and Asia. He holds more than 35 patents, with a significant portion becoming commercially relevant, highlighting his innovative contributions to the field. His extensive publication record, including over 50 publications in international journals and books, as well as his role as an invited speaker at major scientific congresses, further cements his reputation as a leader in pharmaceutical research and innovation.

Global Impact & Collaboration

Dr. Pooth’s global network of experts and key opinion leaders, along with his experience in managing international submission teams and regulatory interactions, illustrates his ability to navigate and influence the global pharmaceutical landscape. His leadership in directing high-level global teams and managing collaborations with regulatory authorities and contract research organizations (CROs) demonstrates his capability to bring innovative products to market successfully.

Publication Top Notes

• “Treatment of Refractory Cardiac Arrest by Controlled Reperfusion of the Whole Body” – A study exploring CARL in a multicenter setting, highlighting its impact on refractory cardiac arrest patients (2023).
• “The Impact of Head Position on Neurological and Histopathological Outcome Following CARL” – Investigates how head positioning affects outcomes in a pig model during CARL (2023).
• “Extracorporeal Cardiopulmonary Resuscitation—Evidence and Implications” – Discusses ECPR’s evidence base and its clinical implications (2023).
• “Effects of Prolonged Serum Calcium Suppression during ECPR in Pigs” – Examines the effects of serum calcium suppression during ECPR, showing implications for treatment strategies (2023).
• “Limiting Calcium Overload after Cardiac Arrest” – Focuses on the role of albumin in reducing calcium overload during CARL (2023).
• “Pervasive Platelet Secretion Defects in SARS-CoV-2 Patients” – Analyzes platelet defects in COVID-19 patients and their potential implications for treatment (2023).
• “CARL – Controlled Reperfusion of the Whole Body” – A book detailing the CARL procedure, providing a comprehensive resource for clinicians (2022).
• “Observational Study on Implications of the COVID-19-Pandemic for Cardiopulmonary Resuscitation” – Examines the pandemic’s impact on resuscitation practices, offering valuable insights (2022).
• “Monitoring Mitochondrial Partial Oxygen Pressure During Cardiac Arrest and ECPR” – A pilot study exploring mitochondrial oxygen monitoring during cardiac arrest in a pig model (2021).
• “Brain Vulnerability and Viability after Ischaemia” – A review on the neurological outcomes following ischemic events, highlighting vulnerabilities and potential treatment avenues (2021).

Conclusion